Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3448 - Enzymatic action of NQO1 attenuates adriamycin-induced cardiotoxicity in mice

Date

10 Oct 2016

Session

Poster display

Presenters

Sei-Hoon Yang

Citation

Annals of Oncology (2016) 27 (6): 526-544. 10.1093/annonc/mdw392

Authors

S. Yang1, D. Khadka2, G. Oh2, H. Kim2, S. Lee2, A. Pandit2, S. Lee2, H. So2

Author affiliations

  • 1 Internal Medicine, Wonkwang University Hospital, 54538 - Iksan/KR
  • 2 1center For Metabolic Function Regulation And Department Of Microbiology, college of Medicine, Wonkwang University, 54538 - Iksan/KR
More

Resources

Abstract 3448

Background

Adriamycin (ADR), a potent anticancer chemotherapeutic agent, used to treat divergent human neoplasms. Its clinical use is limited by various side effects. Various studies have demonstrated that ADR-induced cardiotoxicity is narrated to myocardial oxidative stress, disruption of cellular and mitochondrial Ca2+ homeostasis and DNA damage. Nevertheless, the clear-cut mechanism underlying ADR cardiotoxicity is still not well-defined. Here we describe that development of ADR-induced cardiotoxic mouse model and effect of NAD+/NADH modulation by NQO1 action.

Methods

ADR was intraperitoneally injected on C57BL/6 male mice and WK0202 was orally administrated with 20 mg/kg body weight of mice. Cardiac biomarkers (CPK, Trop I, LDH and SGOT) in plasma levels, oxidative biomarkers and mRNA levels of pro-inflammatory cytokines were assayed.

Results

Cardiac biomarkers in sera, oxidative biomarkers, and mRNA levels of pro-inflammatory cytokines were significantly increased in ADR-treated mice. However, these increases were significantly alleviated by WK0202. We also demonstrated that the drop in SIRT1 and SIRT3 activities is critically involved in ADR-induced cardiotoxicity through acetylation of NF-κB p65 and p53. However, increase of NAD+/NADH by WK0202 through NQO1 enzymatic action attenuated ADR-induced cardiotoxicity through recovery of SIRT1 and SIRT3 activities and subsequent deacetylation of NF-κB p65 and p53.

Conclusions

WK0202 has a protective effect against ADR-induced acute cardiotoxicity through NQO1 enzymatic action. Therefore, WK0202 might be a new therapeutic option for preventing chemotherapy-associated side effects.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

National Fund

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings